NCT05862233
Active, not recruiting
Phase 3
A Phase Ⅲ Clinical Study to Evaluate the Safety and Efficacy of MIL62 Injection in Participants With Primary Membranous Nephropathy
Beijing Mabworks Biotech Co., Ltd.1 site in 1 country150 target enrollmentJune 2, 2023
Overview
- Phase
- Phase 3
- Intervention
- MIL62
- Conditions
- Primary Membranous Nephropathy
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Complete remission rate at Week 76
- Status
- Active, not recruiting
- Last Updated
- 8 months ago
Overview
Brief Summary
This study will evaluate the efficacy, safety, pharmacokinetics(PK) ,pharmacodynamics（PD）and anti-drug antibodies（ADA） of MIL62 compared with cyclosporine in participants with primary membranous nephropathy (pMN).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of primary membranous nephropathy (pMN) according to renal biopsy prior to or during screening;
- •Screening 24-hour urinary protein \>= 5 g after best supportive care for \>= 3 months prior to screening or screening Screening 24-hour urinary protein \> 3.5 g after best supportive care for \>= 6 months prior to screening, or Screening 24-hour urinary protein \> 3.5 g with at least one high-risk factor defined by the protocol;
- •Estimated glomerular filtration rate (eGFR ) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula ≥40 mL/min/1.73 m\^2;
- •If taking ACEI(Angiotensin converting enzyme inhibitors), ARB(Angiotensin receptor blocker), a stable dose within 4 weeks before screening is required;
- •Sufficient organ function;
- •Able and willing to provide written informed consent and to comply with the study protocol.
Exclusion Criteria
- •Participants with a secondary cause of MN;
- •Cyclosporine resistance;
- •Received treatment drugs for membranous nephropathy;
- •Concomitant with other serious diseases；
- •Received live vaccination, major surgery (excluding diagnostic procedures), and participated in other clinical trials within 28 days prior to receiving the first study drug;
- •Patients who are positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb), with HBV DNA levels above the normal range (HBsAg and/or HBcAb-positive patients require regular HBV DNA testing); patients positive for hepatitis C virus (HCV) antibodies; or patients with a positive human immunodeficiency virus (HIV) serology.
- •Participants with CD4+ T lymphocyte count \< 200 cells/μL;
- •Those who have a clear history of tuberculosis or have received anti- tuberculosis treatment;
- •Participants with known history of severe allergic reactions to humanized monoclonal antibodies, MIL62, or Cyclosporine
- •Breastfeeding or pregnant women;
Arms & Interventions
MIL62
Intervention: MIL62
Cyclosporine
Intervention: Cyclosporine
MIL62
Intervention: MIL62
Cyclosporine
Intervention: Cyclosporine
Outcomes
Primary Outcomes
Complete remission rate at Week 76
Time Frame: Week 76
The proportion of participants who achieved complete remission (CR) based on Urine Protein-to-Creatinine Ratio (UPCR) at week 76.
Secondary Outcomes
- Complete Remission rate at Week 52.(Week 52)
- Complete remission rate and Overall remission rate at Week 24 and 104.(Week 24 and 104)
- Complete remission rate and Overall remission rate at Week 24，52，76 and 104.(Week 24，52，76 and 104)
- Time to Treatment Failure or Relapse after Overall remission(Up to 104 weeks)
- Change in efficacy indicators(Baseline to Week 104)
- Overall remission rate at Week 52 and 76.(Week 52 and 76)
- Change in quality of life(Baseline to Week 104)
- Percentage of Participants with Adverse Events (AEs)(up to 104 weeks)
- Percentage of Participants with AEs of Special Interest (AESIs)(Up to 104 weeks)
- Peripheral B-cell Counts at Specified Timepoints(Up to 104 weeks)
- Serum Concentrations of MIL62 at Specified Timepoints(Up to 104 weeks)
- Incidence of ADAs during the study(Up to 104 weeks)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 YearsCystic FibrosisNCT04537793Vertex Pharmaceuticals Incorporated83
Terminated
Phase 3
Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of AgeCystic FibrosisNCT03633526Vertex Pharmaceuticals Incorporated18
Completed
Phase 3
Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of AgeCystic FibrosisNCT03691779Vertex Pharmaceuticals Incorporated71
Active, not recruiting
Phase 2
A Phase 2 Clinical Study of MIL62 in Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT05796206Beijing Mabworks Biotech Co., Ltd.120
Recruiting
Phase 3
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of AgeCystic FibrosisNCT05422222Vertex Pharmaceuticals Incorporated210